Oppenheimer lifts S&P 500 year-end target to Wall Street-high on trade optimism
Oppenheimer Asset Management on Monday raised its year-end target for the S&P 500 index to 7,100, the highest among major Wall Street brokerages, betting on easing trade tensions and strong corporate earnings.
Its current target implies an 11.13 per cent upside to the benchmark index's last close of 6,388.64. Oppenheimer previously set a target of 5,950 for the index.
'With the announcement of trade deals (Japan, EU) by President Trump... we believe that enough 'tariff hurdles' have been overcome for now,' Oppenheimer strategists led by John Stoltzfus said in a note.
The U.S. and European Union finalized a trade deal on Sunday, that sets a 15 per cent tariff on most European goods including cars, semiconductors and pharmaceuticals, while the EU pledged to buy US$750 billion in U.S. energy and invest $600 billion in the U.S. economy.
Last week, U.S. President Donald Trump struck a $550 billion deal with Japan.
Earlier this month, Goldman Sachs, Bank of America, and RBC Capital Markets also raised their S&P 500 targets
The S&P 500 has rebounded 28.2 per cent since its April 8 low, following Trump's 'Liberation Day' tariffs, broadly driven by cyclical sectors such as technology, industrials and communication services.
Oppenheimer brought back its S&P 500 earnings estimate to $275, which it had originally set in December 2024, having trimmed its projection to $265 in April.
Stoltzfus continues to favor U.S. equities, particularly cyclical stocks, and sees further upside as inflation moderates and expects the U.S. Federal Reserve to hold interest rates steady in this week's policy meeting.
(Reporting by Rashika Singh in Bengaluru; Editing by Shailesh Kuber)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
Zacks Investment Ideas feature highlights: CVS Health, Johnson & Johnson and Tenet Healthcare
For Immediate Release Chicago, IL – August 4, 2025 – Today, Zacks Investment Ideas feature highlights CVS Health CVS, Johnson & Johnson JNJ and Tenet Healthcare THC. 3 Medical Stocks to Consider as Markets Take a Breather The broader indexes have cooled off in the last few trading sessions after what was another pleasant month for the stock market in July. While the market has been able to shrug off trade war concerns on the way to a historic rebound, President Trump has officially signed an executive order to hit most of the United States' trading partners with tariff hikes, which ignited a pullback on Friday as July's Jobs Report came in weaker than expected. Considering the benchmark S&P 500 and the tech-centric Nasdaq looked due for a breather after spiking more than +10% in the last three months, investors may be scoping out some defensive positions. That said, these medical sector stocks may continue to provide this defensive safety, as there will always be a constant need for health care. CVS Health Zacks Rank #2 (Buy) CVS Health's transformation into an innovative pharmacy company with integrated offerings across the entire spectrum of pharmacy care is paying off. Thanks to strong earnings, raised guidance, and renewed investor confidence, CVS stock has surged over +30% this year but still trades at just 10X forward earnings and offers a very generous 4.28% annual dividend yield. In addition to sporting a Zacks Rank #2 (Buy), CVS stock currently checks an overall 'A' VGM Zacks Style Scores grade for the combination of Value, Growth, and Momentum. Johnson & Johnson Zacks Rank #2 (Buy) Pharmaceutical giant Johnson & Johnson checks the value box, with a reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield. Furthermore, investors seemed to have flocked to Johnson & Johnson stock earlier in the year during heightened market volatility, and JNJ is still up +15% in 2025 to top the S&P 500 and Nasdaq's returns of roughly +7%. Although Johnson & Johnson's growth has slowed, steady top and bottom line expansion is still in the forecast, and the medical leader has one of the most diversified business models. Having more than 275 subsidiaries, Johnson & Johnson's pipeline of drugs/treatments covers neuroscience and mental health, oncology, immunology, pulmonary hypertension, cardiovascular, rare, and infectious diseases. Tenet Healthcare Zacks Rank #1 (Strong Buy) We'll round out the list with Tenet Healthcare, an investor-owned health care services company that owns and operates general hospitals and health care facilities for urban and rural communities in numerous states. Boasting a Zacks Rank #1 (Strong Buy), THC stock is benefiting from a very pleasant trend of positive earnings estimate revisions. With Tenet Healthcare's annual earnings now expected to leap 25% in fiscal 2025 to $14.92 per share, it's noteworthy that these EPS revisions have climbed 17% in the last 60 days from estimates of $12.69 two months ago. Plus, THC is up +25% YTD and trades at 10X forward earnings. Strongly suggesting Tenet Healthcare's impressive stock performance should continue, FY26 EPS is projected to expand another 4% to $15.48, and estimates have spiked 14% in the last 60 days. On top of being a 'feel-good' investment in regard to Tenet Healthcare reaching underserved communities, THC checks the fundamental trading boxes with an 'A' VGM Zacks Style Scores grade. Bottom Line Hopefully, the excitement for AI-driven growth will continue to push the broader market higher, but these top medical stocks can provide the defensive safety that investors may need with volatility starting to resurface amid President Trump's tariff hikes and last month's unfavorable jobs report. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Johnson & Johnson (JNJ): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
CTV News
7 minutes ago
- CTV News
Canada's economy is showing ‘resilience' against U.S. tariffs. Why?
Canadian and American flags fly near the Ambassador Bridge at the Canada-U.S. border crossing in Windsor, Ont., on Saturday, March 21, 2020. THE CANADIAN PRESS/Rob Gurdebeke OTTAWA — 'Some resilience' — those were the two words Bank of Canada governor Tiff Macklem used last week to describe how the Canadian economy is holding up under the weight of U.S. tariffs. Just a few days later, U.S. President Donald Trump added 35 per cent tariffs on Canadian goods to a running tally that includes hefty duties on steel, aluminum, automobiles and, more recently, semi-finished copper. With tariffs piling up over the past few months, economists say Canada's economy is starting to show cracks — but few signs of collapse. TD Bank economist Marc Ercolao conceded it's a 'bit of surprise' to see the economy holding up against a massive disruption from Canada's largest trading partner. 'Many months ago, ourselves — as well as other economic forecasters — had an outlook for a much weaker Canadian economy. Obviously, that isn't manifesting now,' he said in an interview. 'We are avoiding the worst-case scenario.' What are tariffs doing to the economy? On Thursday, Statistics Canada gave a glimpse at how the economy wrapped up the second quarter of the year when many of those tariffs came into full effect. While the agency sees a couple of small contractions in real gross domestic product by industry in April and May, its flash estimates show the economy rebounding somewhat in June. If those early readings pan out, StatCan said that would be good enough for flat growth overall on the quarter. Some of those results are distorted by volatility — businesses rushing to get ahead of tariffs boosted activity in the first quarter, and that's giving way to weakness in the second quarter, for example. It's still hard to pinpoint exact impacts tied to tariffs, Ercolao said, but a broad trend is emerging. 'What we can say over the last six months or so is that economic activity is somewhat flatlining,' he said. Services sectors are holding up relatively well, but Ercolao said export-heavy industries such as manufacturing and transportation are bearing the brunt of the impact. In an attempt to shore up some of that weakness, the federal government has announced various programs to support tariff-affected workers and broader plans to accelerate defence and infrastructure spending. Macklem noted during his press conference Wednesday that business and consumer confidence are still low, but have improved according to the central bank's recent surveys. And while some trade-exposed sectors have faced job losses and the unemployment has generally trended upward to nearly seven per cent, employers elsewhere in the economy continue to expand their payrolls. 'Consumption is still growing,' Macklem said. 'It's growing modestly. It's certainly being restrained by the uncertainty caused by tariffs. But it is growing and we expect that to continue through the third and fourth quarters.' Will Canada hit a recession? Last week the Bank of Canada kept its policy interest rate unchanged at 2.75 per cent in a third consecutive decision. If the central bank were panicked about the Canadian economy's ability to withstand U.S. tariffs, Ercolao argued it would likely have lowered that rate. The past week's GDP readings were good enough for BMO to raise its outlook for the third quarter into positive territory. Forecasters at the bank now expect Canada will avoid a technical recession this year. BMO chief economist Doug Porter said in a note to clients Friday that Ottawa's personal tax cut at the start of the month and robust demand for domestic travel amid the trade war will boost the economy this quarter, as will 'the less-dire sentiment' around economic forecasts. Some other forecasters continue to pencil a tariff-induced recession into their outlooks. In the Bank of Canada's monetary policy report released alongside the rate decision, it outlined one scenario for the economy assuming the tariff situation remains largely status quo. Canada avoids a recession in that outcome. Growth in 2025 and 2026 remains overall positive, but half a percentage point lower than it would've been without the weight of tariffs. Macklem told reporters that the Bank of Canada would expect the economy to keep growing even with today's tariffs in place, 'but it'll be on a permanently lower path.' 'Unfortunately, the sad reality is that tariffs mean the economy is going to work less efficiently,' he said. What about the new tariffs? Porter said in his note that the actual impact of Trump's new 35 per cent tariff on Canada's economy could be less than headline figure suggests. Because of a carve-out for Canadian exports that are compliant with CUSMA, BMO sees the effective U.S. tariff rate at roughly seven per cent under the new duties, less than a percentage point higher than where it stood before Friday. But with CUSMA up for renegotiation in 2026, Porter said that 35 per cent tariff rate could loom as a 'cudgel' over negotiations — taking full effect if the trade agreement expires without a new deal in place. The Bank of Canada published a separate 'escalation' scenario this week that would see the United States remove Canada's CUSMA exemption as it ramps up global tariffs. Real GDP would drop an extra 1.25 per cent by 2027 in this more severe case; Porter said that this outcome would be 'serious for sure, but far from disastrous.' Ercolao said much of the tariff doom-and-gloom earlier in the year was tied to the speed at which those import duties would be imposed. But the on-again, off-again nature of U.S. trade restrictions to date has given businesses time to adapt to the new way of doing business and constant delays in implementation, he said. 'If we go back to when Trump began his presidency, had he went 100 per cent on his tariff plan right away, we probably would have seen a deep economic contraction just because it would have been so sudden,' Ercolao explained. 'Now we've been afforded that time to at least try to mitigate some of the negative impacts from what these tariffs were expected to do to the Canadian economy.' This report by The Canadian Press was first published Aug. 4, 2025. Craig Lord, The Canadian Press
Globe and Mail
7 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Adobe, Disney, Intuit, Rollins and Johnson & Johnson
For Immediate Release Chicago, IL – August 4, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Adobe Inc. ADBE, The Walt Disney Co. DIS, Intuit Inc. INTU, Rollins Inc. ROL and Johnson & Johnson JNJ. Here are highlights from Friday's Analyst Blog: Buy 5 "Wide Moat" Stocks to Enhance Your Portfolio Returns The wide moat strategy involves investing in companies that not only lead their industries but are also strategically fortified to maintain dominance in the future. The business models of these companies possess durable competitive advantages that shield them from competitors. This strategy isn't just about short-term gains, but securing a portfolio of stocks that can weather economic storms and continue to deliver stable and predictable returns. This investment strategy focuses on companies with unique strengths such as brand recognition, patent protection, proprietary technology and network effects. These moats ensure long-term profitability and market leadership, making the companies resilient in volatile markets. Here we recommend three Wide Moat stocks with a favorable Zacks Rank. These stocks have solid short-term price upside potential. The stocks are Adobe Inc., The Walt Disney Co., Intuit Inc., Rollins Inc. and Johnson & Johnson. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Adobe Adobe has extensively implemented AI applications across its flagship products, such as Photoshop, Illustrator, Lightroom, and Premiere. Earlier this year, ADBE introduced generative AI-driven Adobe Firefly. Moreover, Adobe Acrobat and Reader AI Assistant help users summarize documents and answer questions, saving time and helping them accomplish tasks faster. Using its new AI-driven cloud-based platform, ADBE is also diversifying into digital marketing services, offering data mining services that help businesses measure page views, purchases and social media sites. Adobe Marketing Cloud enables marketers to deliver personalized web experiences across multiple devices, manage multichannel campaigns and optimize media monetization. ADBE has launched Adobe Express, an application for quick editing effects. Leveraging generative AI, this tool is useful for short-form video content like Instagram Reels. Adobe also launched an AI-based Express app for iOS and Android. Adobe has an expected revenue and earnings growth rate of 9.5% and 12%, respectively, for the current year (ending November 2025). The Zacks Consensus Estimate for current-year earnings has improved 0.1% in the last 30 days. The Walt Disney Co. The Walt Disney is benefiting from strength in Domestic Parks & Experiences revenues driven by growth at domestic parks, Disney Vacation Club and Disney Cruise Line, partially offset by decline at international locations including Shanghai Disney Resort and Hong Kong Disneyland Resort. In Entertainment, DIS expects double-digit percentage operating income growth in fiscal 2025. ESPN continues to reinforce its position as a sports-dominant platform, with the second quarter delivering its most-watched primetime ever and 32% viewership growth in the key 18-49 demographic. DIS has successfully transformed its streaming business from a loss-leader to a profitable growth engine. After reporting its first-ever Direct-to-Consumer (DTC) operating profit in fiscal year 2024, the momentum has accelerated in fiscal year 2025 with second-quarter DTC operating income reaching $336 million. The Walt Disney has an expected revenue and earnings growth rate of 4.1% and 16.30%, respectively, for the current year (ending September 2025). The Zacks Consensus Estimate for current-year earnings has improved 0.3% in the last 60 days. Intuit Intuit has been benefiting from steady revenues from the Online Ecosystem and Desktop business segments. INTU's strong momentum in Online Services revenues is driven by the solid performance of Mailchimp, payroll and Money, which includes payments, capital and bill pay. Intuit's generative AI-powered "Intuit Assist," provides a financial assistant, enabling personalized insights and recommendations, integrated into products like TurboTax, Credit Karma, QuickBooks, and Mailchimp, aiming to fuel small business and personal financial success. INTU's Credit Karma business is benefiting from strength in Credit Karma Money, credit cards, auto insurance and personal loans. INTU's strategy of shifting its business to a cloud-based subscription model will help generate stable revenues over the long run. Cloud is a flourishing part of the technology space and has been gaining momentum in recent years. Intuit has an expected revenue and earnings growth rate of 11.7% and 13.7%, respectively, for the current year (ending July 2026). The Zacks Consensus Estimate for current-year earnings has improved 4.3% over the last 90 days. Rollins Rollins stands out with its strategic use of technology and disciplined acquisitions. Tools like BOSS and Orkin 2.0 have redefined ROL's field operations, improved customer service and cut costs. Innovations such as VRM and BizSuite enhance ROL's scheduling and commercial sales, while a strong cash position and zero debt reflect prudent financial management. With 44 acquisitions in 2024 alone and rising dividends, ROL inspires investor confidence and promises long-term growth. Rollins has an expected revenue and earnings growth rate of 10.7% and 12.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.9% over the last seven days. Johnson & Johnson Johnson & Johnson reported strong second-quarter 2025 earnings results wherein both top and bottom lines beat the Zacks Consensus Estimate. JNJ's Innovative Medicine unit is showing a growth trend, driven by key products like Darzalex, Tremfya and Erleada and continued uptake of new launches, like Spravato, Carvykti and Tecvayli. Though in the MedTech segment, JNJ's sales are being hurt due to headwinds in China and competitive pressure in some categories, the Cardiovascular segment is contributing to growth. Johnson & Johnson expects sales growth in both segments to be higher in the second half than in the first. JNJ is making rapid progress with its pipeline and has been on an acquisition spree lately. Johnson & Johnson has an expected revenue and earnings growth rate of 5.2% and 8.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last seven days. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report Intuit Inc. (INTU): Free Stock Analysis Report Rollins, Inc. (ROL): Free Stock Analysis Report
